Abstract:For rare disease drug development, the United States (US) Food and Drug Administration (FDA) has indicated that the same standards as those for drug products for common conditions will be applied. To assist the sponsors in rare disease drug development, the FDA has initiated several incentive programs to encourage the sponsors in rare disease drug development. In practice, these incentive programs may not help in achieving the study objectives due to the limited small patient population. To overcome this problem, some out-of-the-box innovative thinking and/or approaches, without jeopardizing the integrity, quality, and scientific validity of rare disease drug development, are necessarily considered. These innovative thinking and/or approaches include but are not limited to (i) sample size justification based on probability statements rather than conventional power analysis; (ii) demonstrating not-ineffectiveness and not-unsafeness rather than demonstrating effectiveness and safety with the small patient population (i.e., limited sample size) available; (iii) the use of complex innovative designs such as a two-stage seamless adaptive trial design and/or an n-of-1 trial design for flexibility and the efficient assessment of the test treatment under study; (iv) using real-world data (RWD) and real-world evidence (RWE) to support regulatory submission; and (v) conducting an individual benefit–risk assessment for a complete picture of the clinical performance of the test treatment under investigation. In this article, we provide a comprehensive summarization of this innovative thinking and these approaches for an efficient, accurate and reliable assessment of a test treatment used for treating patients with rare diseases under study. Statistical considerations including challenges and justifications are provided whenever possible. In addition, an innovative approach that combines innovative thinking and these approaches is proposed for regulatory consideration in rare disease drug development.

Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Adaptive seamless design for establishing pharmacokinetics and efficacy equivalence in developing biosimilars

Elastic Meta-Analytic-predictive Prior for Dynamically Borrowing Information from Historical Data with Application to Biosimilar Clinical Trials.

Innovation drug approvals based on a bridging study: from concept to practice

A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)

A Design For Survival Studies: A Multi-regional Trial With Unrecognized Heterogeneity

Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations

Bridging Studies in Clinical Trials for New Drug Application

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Clinical trial design in biosimilar drug development

Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars

Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary

BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials

Impact of Switching on Pharmacokinetics of Therapeutic Biologics and Interchangeability Assessment-A Simulation Study.

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment

Novel Design and Analysis for Rare Disease Drug Development

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test